News
The Smartest Stocks to Buy With $20 Right Now and Hold Forever
You don't need a lot of money to get going in the market these days. The growing popularity of zero-commission trading means that even $20 is more than enough to buy a piece of a potentially
AT&T Stock Is Still Dirt Cheap After Surging Nearly 20%
Shares of telecom giant AT&T (NYSE: T) have been stuck in a rut for much of 2023. Slowing subscriber growth, an uncertain economic outlook, mountains of debt, and fear that the company's free cash
Is This Healthcare Stock's 10% Yield a Steal of a Deal or Too Good to Be True?
A dividend yield can tell you a lot about a payout. Not only does it tell you how much you could be collecting in dividend income, but it can give you an indication of investor sentiment, and
EQS-News: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
EQS-Adhoc: Ad hoc: MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
Eyeing Bonds Because of High Interest Rates? Try These 2 Dividend Stocks Instead
The Federal Reserve (Fed) is the central bank of the U.S., responsible for regulating banks, implementing monetary policy, and maintaining the financial system's stability. One aspect of the latter
EQS-Adhoc: Bayer Aktiengesellschaft: OCEANIC-AF study stopped early due to lack of efficacy
Here's Why I Like AT&T Stock
Dividend stocks offer many potential benefits to investors. They can provide income, boost returns through dividend reinvestment plans, act as a hedge against inflation and economic downturns, and
Could Investing $10,000 In CRISPR Therapeutics Stock Make You a Millionaire?
All eyes have been on CRISPR Therapeutics (NASDAQ: CRSP) in recent times because the biotech company has reached a key moment. CRISPR Therapeutics and partner Vertex Pharmaceuticals are awaiting
Is Beam Therapeutics Stock a Buy Now?
When it comes to gene-editing companies on the cutting edge, Beam Therapeutics (NASDAQ: BEAM) is keen to be one of the leaders. While it's a bit of a laggard in terms of its pipeline's maturity
3 Monster Stocks in the Making
Most, if not all, of the market's current mega-cap stocks started out much smaller. Investors who spotted their potential early had opportunities to make fortunes over time.
Which smaller stocks
You Don't Have to Pick a Winner in Biotech. Here's Why.
The biotech company that's able to deliver the next game-changing treatment might become tomorrow's winner -- and offer your portfolio a giant boost.
Problem is, it's not always easy to identify
Why CRISPR Therapeutics Stock Is Jumping Again Today
Shares of CRISPR Therapeutics (NASDAQ: CRSP) were jumping 10.1% higher as of 10:58 a.m. ET on Friday. The solid move followed Thursday's gain of more than 8%.
There's a good reason for this
AstraZeneca Is Trying to Make an Ozempic Competitor (Again), but Don't Rush to Buy the Stock
U.K.-based AstraZeneca (NASDAQ: AZN) is now gearing up for the second time to develop a challenger to Novo Nordisk's (NYSE: NVO) Ozempic, its absurdly successful treatment for type 2 diabetes. If
Is Vertex Pharmaceuticals Stock a Buy Now?
If past performance guaranteed future success, Vertex Pharmaceuticals (NASDAQ: VRTX) would be one of the best biotech stocks to invest in. The drugmaker has consistently outperformed the broader
AbbVie and Pfizer Have 1 Thing in Common: Their Biggest Products Are on the Decline. Time to Sell?
AbbVie (NYSE: ABBV) and Pfizer (NYSE: PFE) are makers of two of the world's top-selling pharmaceutical products. AbbVie's immunology drug Humira brought in peak sales of more than $21 billion, while
EQS-News: HAEMATO AG publishes figures for the third quarter of 2023: Sales increase of around 13% compared to the same period of the previous year, strong increase in EBIT margin and significant increase in
EQS-News: MorphoSys AG Reports First Nine Months and Third Quarter 2023 Financial Results
EQS-Adhoc: Termination of the botulinum toxin project
2 Healthcare Stocks That Could Make You Richer
As far as healthcare stocks go, drugmaker Merck (NYSE: MRK) and medical device expert Intuitive Surgical (NASDAQ: ISRG) haven't been the best of the bunch this year. Both are lagging the market in
Could a Short Squeeze Be Coming for These 3 Heavily Shorted Stocks?
Wall Street traders have numerous (and often creative) strategies to speculate on stocks and their up and down price movements. There are times when the prices of stocks are influenced more by what
EQS-News: Evotec presents precision medicine platforms for accelerated pipeline building at Capital Markets Day
CorMedix (CRMD) Q3 2023 Earnings Call Transcript
Image source: The Motley Fool.
CorMedix (NASDAQ: CRMD)Q3 2023 Earnings CallNov 14, 2023, 4:30 p.m. ET
Operator
Source Fool.com
Better Growth Stock: Pfizer vs. Novo Nordisk
Both Pfizer (NYSE: PFE) and Novo Nordisk (NYSE: NVO) can claim to investors that plenty more growth is on the way. With new markets beckoning and multi-year strategic plans in full swing, both of
Is AT&T Stock a Good Long-Term Investment?
An investment in AT&T (NYSE: T) stock looks appealing on the surface right now given its hefty dividend yield of around 7%. However, the telecom giant's substantial long-term debt load of $126.7